Clinical Report: The Role of Complement in Immune and Vascular Diversity Among Preeclampsia Subtypes
Background
Preeclampsia is a significant cause of maternal and perinatal morbidity, affecting 2-8% of pregnancies globally. Traditionally viewed as a hypertensive disorder, it is increasingly recognized as a heterogeneous syndrome with varying biological mechanisms.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Preeclampsia is characterized by diverse biological origins, including placental insufficiency and maternal cardiometabolic dysfunction.
Complement activation patterns differ among PE subtypes: classical pathway activation in early-onset PE and alternative pathway activation in late-onset PE.
Dysregulation of the complement system contributes to endothelial injury and inflammation in PE.
Current diagnostic and therapeutic approaches for PE are largely non-specific and do not account for biological heterogeneity.
A proposed framework links complement dysregulation to disease trajectories and identifies potential biomarkers and therapeutic targets.
Clinical Implications
The proposed complement-centered model of preeclampsia emphasizes the need for precision diagnostics and mechanism-guided therapy. This approach could enhance risk stratification and support the development of targeted interventions tailored to individual disease mechanisms.
Conclusion
Redefining preeclampsia as a complement-stratified syndrome may provide a foundation for improved diagnosis and treatment strategies. This model highlights the importance of understanding the biological diversity of the disease.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
